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Background: A major goal of the field of systems biology is to translate genome-wide profiling data (e.g., mRNAs,
miRNAs) into interpretable functional networks. However, employing a systems biology approach to better
understand the complexities underlying drug resistance phenotypes in cancer continues to represent a significant
challenge to the field. Previously, we derived two drug-resistant breast cancer sublines (tamoxifen- and
fulvestrant-resistant cell lines) from the MCF7 breast cancer cell line and performed genome-wide mRNA and
microRNA profiling to identify differential molecular pathways underlying acquired resistance to these important
antiestrogens. In the current study, to further define molecular characteristics of acquired antiestrogen resistance
we constructed an “integrative network”. We combined joint miRNA-mRNA expression profiles, cancer contexts,
miRNA-target mRNA relationships, and miRNA upstream regulators. In particular, to reduce the probability of false
positive connections in the network, experimentally validated, rather than prediction-oriented, databases were
utilized to obtain connectivity. Also, to improve biological interpretation, cancer contexts were incorporated into
the network connectivity.
Results: Based on the integrative network, we extracted “substructures” (network clusters) representing the drug
resistant states (tamoxifen- or fulvestrant-resistance cells) compared to drug sensitive state (parental MCF7 cells). We
identified un-described network clusters that contribute to antiestrogen resistance consisting of miR-146a, -27a,
-145, -21, -155, -15a, -125b, and let-7s, in addition to the previously described miR-221/222.
Conclusions: By integrating miRNA-related network, gene/miRNA expression and text-mining, the current study
provides a computational-based systems biology approach for further investigating the molecular mechanism
underlying antiestrogen resistance in breast cancer cells. In addition, new miRNA clusters that contribute to
antiestrogen resistance were identified, and they warrant further investigation.
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Endocrine therapy is a highly effective form of adjuvant
therapy for hormone sensitive breast cancer. Currently,
the three classes of commonly used drugs for adjuvant
endocrine therapy are selective estrogen receptor modula-
tors (SERMs, e.g., tamoxifein), selective estrogen receptor
down-regulators (SERDs, e.g., fulvestrant), and aromatase
inhibitors (AIs). Unfortunately, tumor cells often develop
resistance to endocrine therapy [1], representing a major
obstacle limiting the success of breast cancer treatment.
To better understand the biology and molecular mechan-
isms that underlie endocrine resistance, we and others
have developed tamoxifen- and fulvestrant-resistant breast
cancer cell models [1,2]. We demonstrated that dramatic-
ally different molecular mechanisms underlie progression
to resistance to tamoxifen (henceforth, MCF7-T) and
fulvestrant (henceforth, MCF7-F) and also identified spe-
cific genes and biochemical pathways associated with
SERM- and SERD-resistance.
Recently, microRNAs (miRNAs), a novel noncoding
RNA class [3-5], have been shown to be key regulators of
various biological processes and diseases [3,6]. In breast
cancer, alterations in expression of miRNAs appear to play
important roles in drug resistance [7,8] and thus may rep-
resent new therapeutic targets. Furthermore, the role of
specific miRNAs in antiestrogen (fulvestrant, tamoxifen)
resistant breast cancer has been investigated by us [9] and
others [10,11], and both Rao et al. [9] and Miller et al. [10]
demonstrated a critical role for miR-221/222 in SERM
and SERD resistances as well as a key role in estrogen
receptor alpha (ERα) biology and function. In this follow-
up study, we took a global approach to further investigate
the role of miRNAs in resistance to these important endo-
crine therapies.
Although methods for the functional analysis of miRNAs
are publicly available [12-14], systematic global view [15,16]
of the networks of these key epigenetic regulators has not
been fully explored. Systems biology [17] approaches have
recently been used to examine miRNA-mediated patho-
genic dys-regulation [15,18,19] and oestrogen-regulated
miRNAs [20]; however, this approach has only recently
been used to investigate breast cancer drug resistance [21],
one of the most lethal cancers in women. Here, we present
an integrative view of “antiestrogen resistance-related
miRNA-mRNA regulation” and discuss functional roles of
this previously un-described network. The network was
reconstructed by combining cancer contexts and expres-
sion profiles for miRNAs and mRNAs. Furthermore, in
order to minimize false positives in the network construc-
tion [4], we utilized experimental evidence-based prior
knowledge databases [22,23], including miRNA-target
mRNA relations and miRNA upstream regulators (e.g., up-
stream signaling proteins, transcription factor binding sites
(TFBSs) in miRNA promoters). The use of cancer contexts[24] provided further biological interpretability for the net-
work construction. To simplify the network, we determined
the underlying substructures (henceforth, network clusters).
Notably, in addition to the known miR-221/222-mediated
network cluster [9-11], we identified novel miRNA-related
network clusters associated with antiestrogen-resistant
breast cancer [9-11]. Interestingly, the novel network
clusters contained genomic instability, a recently described
hallmark of cancer [24] and area of intense interest in the
breast cancer field [25].
Results and discussion
Overview
Our goal was to identify a global miRNA-regulated land-
scape in drug-resistant breast cancer cell lines (MCF7-F,
MCF7-T) compared to MCF7 (Additional file 1). To im-
prove the reliability of our approach, experimentally vali-
dated miRNA-related databases were used to construct an
“evidence-based” miRNA-mRNA network. The network
consisted of miRNAs, their targets, transcription factors
(TFs) binding to miRNA promoters, and signaling mole-
cules upstream of miRNAs. We further expanded the
network by associating it with biological contexts, includ-
ing the important hallmarks of cancer (henceforth, cancer
contexts) [24]. The associations were inspected by utiliz-
ing a text-mining tool, PubGene [26]. Subsequently, the
expression data for both miRNAs and mRNAs [2] were
incorporated into the network. In order to observe differ-
ential usage (or identical usage) of the fully integrative
network, we examined two different drug resistance states
(MCF7-T, MCF7-F) and then refine topologically import-
ant network clusters underscoring the network. The
details are described in Methods.
Integrative network description
The integrative network (Figure 1) demonstrated that
the entries (e.g., miRNAs, mRNAs) were extensively
interconnected with eight cancer-related hallmarks [24],
suggesting that miRNA-driven epigenetic changes in
these hallmarks [27] contributed to the resistance of
MCF7 cells to antiestrogens. Furthermore, both com-
mon and differential network usages were observed
between the two drug resistance states. To validate the
network regulations (Figure 1), we used the mean correl-
ation across all the edges (in the network) as a statistic
[19] and performed 5000 node label permutations. As a
result, the regulations or the associations in the network
were statistically significant at p-value 0.000 (see the
details in Additional file 2).
Network cluster analysis
To further identify important network clusters associated
with tamoxifen and fulvestrant resistance, we dissected
the integrative network by using a Cytoscape [28] plug-in,
Figure 1 Integrative network view of antiestrogen resistant breast cancer cells. Expression patterns of the network were depicted in (a)
MCF7-T over MCF7 and (b) MCF7-F over MCF7. The TFs, the signaling proteins, and the miRNA target genes were functionally involved in
“hallmarks of the cancer” suggested by Hanahan and Weinburg [24]. The hexagon denotes miRNA target mRNAs (from miRTarBase),
protein-coding genes corresponding to TFs (from TransmiR), and signaling proteins (from TransmiR). The triangle denotes the miRNAs, and the
rectangle the cancer contexts. The number of connections in a node corresponds to the node size. The blunt-ended solid edge in blue
represents miRNA-mediated target mRNA inhibition. The circle-ended dashed edge in black represents a TF binding to the miRNA promoter, or
denotes an upstream signaling protein regulating the miRNA. The grey solid edge indicates association between the cancer contexts and the
protein coding genes (including miRNA target mRNAs). The fold change color scale bar is represented in the bottom. Far left values (minimum)
and far right values (maximum) in the scale bar are 0.039 and 12.4 for MCF7-F/MCF7, and 0.083 and 5.3 for MCF7-T/MCF7.
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orphan network clusters. We then selected the top 10
largest clusters having at least five elements (Figure 2). As
cluster 1 showed the strong associations with cancer hall-
marks, we examined this cluster in greater detail (below).
Cluster 1 contained both differential and common
usages by miRNAs and their targets. The miRNAs and
mRNAs relating to the two drug resistant states were
associated specifically with various cancer contexts
(genomic instability, cell death, epithelial-mesenchymal
transition (EMT), drug resistance neoplasm, glycolysis,
receptors cytokine) [24]. Mir-146a was down-regulated
in both drug resistant cell lines, and its targets, BRCA1/
2, were up-regulated in the cluster. Mir-146a is consid-
ered to function as a tumor suppressor [30,31] in a
tissue-dependent context [32], while BRCA1/2 are well
known tumor suppressors involved in maintaining gen-
ome-integrity, cell cycle, and DNA damage response
(DDR) [33,34]. Despite up-regulation of these tumor
suppressor genes (TSGs), which would contribute to
increased genome stability, it is possible that TSG bindingpartners could negatively affect genome maintenance [34].
Therefore, we examined expression changes of BRCA1/2
partners in the two resistant cells compared to MCF7. As
shown in Additional file 3, expression of BRCA1/2 bind-
ing partners was deregulated [33,34]. A recent study [35]
proposed that excess of error-free homologous recombin-
ation (HR), a critical process for maintaining genomic
integrity, can result in genomic instability and that fine-
tuning may be coordinated in the DDR pathway, DNA
repair, chromosome segregation, and cell cycle control.
Thus, during development of resistance to tamoxifen and
fulvestrant, BRCA1/2 binding partner expression changes
may be detrimental not only to cell cycle checkpoint [33]
but also to the DDR pathway, an important pathway in
genomic stability [34]. Although TSGs BRCA1 and BRCA2
were up-regulated in MCF7-F and MCF7-T compared to
the parental MCF7 cell line, BRCA1/2 up-regulation may
affect fine-tuning of genomic integrity [35].
As mutations are also known to be critical for drug
resistance [36,37], we examined publicly known somatic
mutations associated with cluster 1. Somatic mutation of
Figure 2 The 10 network clusters by the clusterMaker. (a) Expression of MCF7-T over MCF7 was color-coded in the clusters. (b) Expression of
MCF7-F over MCF7 was color-coded. The circle-ended dashed edge in black represents a TF binding to the miRNA promoter, or denotes an
upstream signaling protein regulating the miRNA. The grey solid edge indicates association between the cancer contexts and the protein coding
genes (including miRNA target mRNAs). The blunt-ended solid edge in blue represents miRNA-mediated target mRNA inhibition. The color scale
description is same with Figure 1.
Nam et al. BMC Genomics 2012, 13:732 Page 4 of 8
http://www.biomedcentral.com/1471-2164/13/732PIK3CA in MCF7 has been reported in the COSMIC
database (www.sanger.ac.uk/genetics/CGP/cosmic/) [38]
and recent studies [36,37] have reported an association
between PIK3CA mutation and breast cancer drug resist-
ance. Our analysis of the two sublines indicates that PI3K/
AKT mutation resulting in signaling activation may con-
tribute to the development of antiestrogen resistance.
Such PI3K/AKT activation may also induce phosphoryl-
ation, ubiquitination, and nuclear export of CHK1 [39],
resulting in genomic instability. We further speculate that
PIK3CA mutation in MCF7 cells could acquire gain-of-
function (e.g., PI3K/AKT activation) during development
of antiestrogen resistance, resulting in genomic instability
and contributing to the resistant phenotypes. Interestingly,
AKT1 activation has been reported to cause genomic
instability via nuclear localization of BRCA1 [40], and
PI3KCA (upstream of AKT1) mutation could affect DDR
pathway by Brca1 protein localization.
MiR-27a and miR-145, by regulating their targets, were
involved in MeSH terms EMT, glycolysis, drug resistanceneoplasm, cell death, and receptors cytokines. Mir-27a is
known to induce paclitaxel-resistance in ovarian cancer
cells by targeting HIPK2, followed by reduced MDR1
expression [41]. Thus, it is tempting to speculate that
fulvestrant resistance may possibly share the same mech-
anism with paclitaxel. Mir-145 was slightly up-regulated
in MCF7-T and down-regulated in MCF7-F. By repres-
sing various targets, mir-145 has been known to nega-
tively regulate EMT and metastasis [3,42] via STAT1 and
IGF1R [43,44]. In our previous study [2], we validated
that MCF7-F cells had not only reduced cell-cell con-
tacts but increased malignant morphology and char-
acteristics (e.g., increased migration and invasion)
compared to the other two cell lines (MCF7, MCF7-T),
indicating that MCF7-F underwent EMT and further
malignancy. Cluster 1 further indicates a key role for
miR-145 down-regulation in fulvestrant resistance, per-
haps due to altered regulation of EMT and malignant
progression. In addition, because IGF1R is not only an
upstream regulator of metabolism (e.g., glycolysis) but
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regulator of both metabolism and a signaling pathway
(JAK/STAT pathway). In summary, cluster 1 shows that
miR-146a and BRCA1/2 are shared molecular characteris-
tics of the tamoxifen and the fulvestrant resistances (gen-
omic stability fine-tuning, PI3KCA mutation) and are
closely associated in terms of the DDR pathway (e.g. HR).
MiR-145 may contribute to the differences in epigenetic
background between the two distinct forms of antiestro-
gen resistance.
Clusters 2 and 4 describe the differential two drug-
resistant states in terms of miRNA-target interaction,
because the two miRNAs (miR-21, miR-155) and their
targets show opposite expression. In particular, miR-21
plays an important role both in cancer as well as in stem
cell biology [45], inducing EMT and thus contributing to
migration, invasion, and morphological change. MiR-21
up-regulation is also consistent in the cell morphology
changes associated with acquired antiestrogen resistance
[2]. MCF7-T cells grow as tightly packed colonies with
limited cell spreading, while MCF7-F cells, by contrast,
show reduced cell-cell contacts compared with MCF7 or
MCF7-T cells and are loosely attached to the culture
surface. Thus, the target genes of the miRNA in this
cluster (TIAM1, BASP1, EIF2S1) [46,47] could be
involved in EMT as well as in malignant transformation
of MCF7-F. In addition, expression of the TFs (AP1S2,
AP1G1) upstream of miR-21 was differentially changed
between the two drug resistant cell lines and the differ-
ential TF usage could also contribute expression changes
of this miRNA.
In cluster 4, mir-155 and its targets showed opposite
expression patterns in MCF7-T and MCF7-F and thus
could contribute to the different drug-resistant states.
As the majority of studies indicate that miR-155 is an
oncogene [48], this miRNA could play a role in acquired
resistance to tamoxifen. However, depending on the bio-
logical context, it has been suggested that miR-155 may
have a tumor suppressor role [49,50]. Thus, we cannot
exclude the possibility that different cellular contexts
could also contribute to the distinct drug-resistant
phenotypes.
Clusters 5, 6, and 7 have the same expression patterns
between MCF7-T and -F, implying that the three clusters
could be involved in common molecular mechanisms
underlying acquired resistance to SERMs and SERDs.
Let-7b, miR-15a, and miR-125b were up-regulated in
both antiestrogen-resistant cell lines. In particular, miR-
125b has been reported to play important roles in drug-
resistance [51] and may be an oncogene [52] in breast
cancer. Experimental validation of the functional roles of
miR-125b target mRNAs (CGN, CASC3, EIF4EBP1,
LYPLA2) during acquired antiestrogen resistance is
ongoing in our laboratory.Clusters 3 and 9 were of interest in terms of mutual
regulatory loops. The miR-222 and CDKN1B (p27Kip1)
loop in cluster 3 was conserved in MCF7-T and -F in
terms of expression, while SIP1 and miR-429 in cluster 9
showed an opposite expression pattern. In particular,
miR-222 [9-11] in cluster 3 is closely aligned with ERα
status and antiestrogen resistance.
Conclusions
We applied a systems biology approach [15,53] to
MCF7-derived drug resistant cell lines by utilizing miR-
NAs, mRNAs and text-mining. By using the systems
approach to examine global miRNA-target mRNA net-
work in the context of the hallmarks of cancer [24], we
identified several important network clusters involved
not only in antiestrogen resistance mechanisms but also
in differentiating resistance to SERMS and SERDS. To
date, only miR-221/222 has been shown to be involved
in SERM- and SERD-resistance as well as in ERα status.
Our computation reveals that multiple microRNA-
related network clusters (Figure 2), in addition to the
miR-221/222 network cluster, may contribute to anties-
trogen resistant breast cancer cells. Recent reports
[54,55] appropriately advocate the need for validating
miRNA microarray data. Despite this limitation of the
current study, we utilized miRNA-oriented network as
well as cancer contexts to implement a systems biology
approach in the field of breast cancer and antiestrogen
resistance.
Methods
Microarray analysis of mRNA and microRNA in MCF7,
MCF7-F, and MCF7-T cells
ERα-positive MCF7 cells and their tamoxifen- (MCF7-T)
and fulvestrant-resistant (MCF-F) daughter cells were
cultured as previously described [2]. For gene expression
studies, total RNA was isolated using RNeasy Mini Kits
(Qiagen, Valencia, CA, USA), converted to cRNA,
labeled and hybridized to Affymetrix U133 Plus 2.0
arrays (Affymetrix, Santa Clara, CA, USA) by the
Indiana University Center for Medical Genomics. For
microRNA isolation, pelleted cells were resuspended in
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) (which
retains small RNA molecules), subjected to polyethylene
glycol precipitation, RNA ligase-mediated labeling, and
hybridized to a custom array, according to previously
published method [56]. Quantile normalization [57] was
used in both mRNA and miRNA microarrays (Additional
files 4 and 5). Each cell line had two replicates in both
miRNA and gene expression microarrays.
Databases
We downloaded the miRNA-related databases [22,23] in
order to analyze miRNA-mRNA relations. For better
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(release 4.2) [22] and TransmiR (v1.1) [23] including only
experimentally validated evidences based on literatures,
were considered in the study. TransmiR [23] contains
upstream regulators (TFs or upstream signaling mole-
cules) controlling miRNA transcription, and miRTarBase
[22] has the mRNA targets of miRNAs. The different gene
identifier usages in the two databases were converted
to gene symbols by using UCSC Genome Browser [58].
The expressions (fold changes) of mRNAs and miRNAs
belonging to the two databases were obtained from both
miRNA and mRNA microarrays.
Network construction
We combined the relationships between miRNAs and
their upstream regulators (from TransmiR) with those be-
tween miRNAs and their target genes (from miRTarBase).
In network construction, we restricted the target genes to
TF-encoding genes and signaling protein-encoding genes
because the two entities, TFs and miRNAs, play important
roles in regulation, propagation and cellular fate [59].
We defined the integrated relation, “upstream regulator-
miRNA-target”, as a circuit. We applied a well-known
condition [14], inverse expression between miRNAs and
their targets, for further refining the circuits based on the
microarray expressions.
Integration of cancer biology-related contexts and circuits
PubGene (www.pubgene.org) [26] was used to connect
cancer-related context with the regulators (e.g., TFs, sig-
naling molecules) and targets of miRNAs. The contexts
were obtained from the hallmarks of cancer proposed by
Hanahan and Weinberg [24]. The contexts are related to
sustaining proliferative signaling, evading growth sup-
pressors, deregulating cellular energetics, resisting cell
death, genome instability, inducing angiogenesis, activat-
ing invasion and metastasis. It is noted that immunosup-
pression, one of the hallmarks, was not inspected
because immune cells are not included in the in vitro
cell culture conditions. The hallmarks were mapped to
appropriate MeSH (www.ncbi.nlm.nih.gov/mesh) terms
in the PubGene: mutation, cyclin dependent kinase
inhibitor proteins, cell death, receptors cytokine, drug
resistance neoplasm, angiogenesis inducing agents, gly-
colysis, epithelial-mesenchymal transition, and genomic
instability. We added “mRNA-MeSH term” relations
(grey solid lines in Figures 1 and 2) into the network of
the circuits obtained from the previous section. The
integrative network of the circuits and MeSH terms was
constructed and subsequently visualized on Cytoscape
[28]. In order to obtain the network clusters, the cluster-
Maker [29] was applied to the integrative network. Each
node was color-coded by its fold-change of its subline
(MCF7-F or MCF7-T) over its parental cell line (MCF7).Additional files
Additional file 1: Study overview. Integrative network with miRNAs,
mRNAs, expressions, and cancer-related contexts in acquired resistance to
antiestrogen in breast cancer cells (tamoxifen resistant (MCF7-T),
fulvestrant resistant (MCF7-F), and parental drug-sensitive MCF7 cells). For
minimizing false positives in network connectivity, we used
experimentally validated databases: TransmiR (TFs binding in miRNA
promoters, signaling proteins for regulating miRNAs), and miRTarBase
(miRNA target information). In addition, biological interpretability was
enhanced by incorporating cancer-related context terms suggested by
Hanahan and Weinberg [24] into the network connectivity. The cancer
contexts were connected with TFs, signaling proteins, and miRNA targets
from the two databases by using a text-mining tool, PubGene [26]. The
antiestrogen resistant cell line expressions were incorporated into the
network connectivity (see the details in the Methods section), and the
network clusters underscoring the antiestrogen resistances were
identified by the Cytoscape clusterMaker [29].
Additional file 2: Statistical validation of the regulations in the
network. The detailed information is described in this material.
Additional file 3: Genes involved in molecular mechanisms of DNA
damage response via BRCA1 and BRCA2. The genes listed refer to Roy
et al. [34].
Additional file 4: Fold-change of mRNAs. The fold changes of
MCF7-T over MCF7 and MCF7-F over MCF7 were summarized from
our previous study [2]. The positive fold change means that the drug-
resistant cell line is greater than MCF7, and the negative fold change vice
versa.
Additional file 5: The processed expression of miRNA microarrays.
The expression values were log2-transformed.
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